Hematologic Disorders Education Center

Hematological disorders present an enormous set of challenges for clinicians. Healthcare providers are thankful that the treatment alternatives for these disorders are improving at a significant rate and that patient outcomes are improving as well.

The challenge for many clinicians is to keep track of the new pharmacologic approaches to treating hematological disorders. This website has been designed as a resource center for hematologists, oncologists, and other healthcare providers who are involved in the care of these patients.

AML Mutations May Influence Immune Function After Stem Cell Transplant

AML Mutations May Influence Immune Function After Stem Cell Transplant

A study published in the New England Journal of Medicine found that hematopoietic stem cell transplantation did not produce different mutations in patients with acute myeloid leukemia who relapse after transplantation...
Ruxolitinib Provides Better Control in PV Than Other Therapies

Ruxolitinib Provides Better Control in PV Than Other Therapies

The RESPONSE and RESPONSE-2 trials found that ruxolitinib, a Janus kinase 2 (JAK2) inhibitor, provided far better hematocrit control and was better tolerated than interferon in patients with HU resistance or intolerance, according to a study published in the Annals of Hematology...
European LeukemiaNet Consortium Releases New Guidelines for Myeloproliferative Neoplasms

European LeukemiaNet Consortium Releases New Guidelines for Myeloproliferative Neoplasms

The European LeukemiaNet Consortium recently updated its guidelines for treating Philadelphia chromosome-negative myeloproliferative neoplasms for the first time since 2011. These classical myeloproliferative neoplasms (MPNs) include polycythemia vera (PV), essential thrombocythemia (EV) and primary myelofibrosis (MF)...
JAK2 Inhibitors Improve Response, Survival and Control in MPNs

JAK2 Inhibitors Improve Response, Survival and Control in MPNs

The last decade has seen tremendous advances in the myeloproliferative neoplasms (MPNs), polycythemia vera (PV), essential thrombocythemia (ET) and myelofibrosis (MF). Genetic profiling demonstrated that all patients with MPNs have activated JAK2 signaling...
FDA Approves First Pegfilgrastim Biosimilar for Patients Receiving Chemotherapy

FDA Approves First Pegfilgrastim Biosimilar for Patients Receiving Chemotherapy

The FDA approved Udenyca, the first pegfilgrastim biosimilar, for patients receiving myelosuppressive chemotherapy...

Loading...